- Home
- TTGT vs AMRN Comparison
TTGT vs AMRN Comparison
Compare TTGT & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | AMRN |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.9M | 339.8M |
| IPO Year | 2007 | 1993 |
Fundamental Metrics
Financial Performance| Metric | TTGT | AMRN |
|---|---|---|
| Price | $5.42 | $16.53 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 4 | 1 |
| Target Price | $11.25 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 478.9K | 78.3K |
| Earning Date | 11-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $446,514,000.00 | $226,733,000.00 |
| Revenue This Year | $74.33 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.55 | N/A |
| 52 Week Low | $4.63 | $7.08 |
| 52 Week High | $28.44 | $20.90 |
Technical Indicators
Market Signals| Indicator | TTGT | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 50.35 |
| Support Level | $4.71 | $15.36 |
| Resistance Level | $5.42 | $16.25 |
| Average True Range (ATR) | 0.29 | 0.69 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 94.87 | 58.20 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.